Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. (NASDAQ: YI) is a tech-enabled healthcare platform company operating in China’s healthcare ecosystem. Its news flow is closely tied to its role in pharmaceutical product distribution, online healthcare services, and digital enablement of pharmacies and upstream partners. Company announcements often describe how 111, Inc. is reshaping the healthcare value chain by connecting consumers, pharmacies, and pharmaceutical companies through online and offline channels.
Investors following YI news can expect regular earnings and financial results updates, including unaudited quarterly results furnished on Form 6-K. These releases detail performance in the company’s B2B and B2C segments, trends in operating expenses, gross segment profit, and the use of non-GAAP measures such as non-GAAP income from operations and non-GAAP net income or loss. Management commentary in these announcements frequently addresses operational efficiency, cash flow, and progress on strategic initiatives.
Another key category of news involves strategic and operational developments. Recent disclosures describe a transition from an asset-heavy to an asset-light business model, including the divestiture of self-operated subsidiaries that have become warehouse partners. The company also reports on supply chain and logistics initiatives, such as the "MANTIANXING" project and the Kunpeng Network, which are intended to enhance fulfillment capabilities and efficiency.
111, Inc. also issues news about capital markets and compliance events, such as regaining compliance with Nasdaq listing requirements and changes to its ADS ratio. In addition, the company announces participation in investor events and fireside chats where management discusses earnings, strategic priorities, and the macroeconomic environment. For investors and observers of China’s digital healthcare and pharmacy distribution space, the YI news stream provides ongoing insight into the company’s financial performance, strategic direction, and technology-driven initiatives.
111, Inc. (NASDAQ: YI) reported third quarter 2025 unaudited results, highlighting a strategic shift to an asset-light model and improved cash generation.
Key metrics: net revenues RMB3.0 billion (down 16.7% YoY), gross segment profit RMB178.0 million (down 15.5% YoY), net cash from operating activities RMB38.1 million, and positive operating cash flow YTD RMB89.3 million. The company completed divestitures of three self-operated subsidiaries to become fulfillment partners, citing strengthened liquidity and profitability. The MANTIANXING supply-chain initiative reported GMV +20.5% and customer count +31.0% vs Q2.
111, Inc. (NASDAQ: YI) reported Q2 2025 financial results showing maintained operational profitability despite challenging market conditions. Net revenues decreased 6.4% to RMB3.2 billion (US$447.5 million) compared to the same quarter last year. The company achieved a 9.3% reduction in operating expenses to RMB185.3 million, representing 5.8% of net revenues, an improvement of 20 basis points year-over-year.
Key operational highlights include a 53.6% increase in marketing promotional products sales and 19% growth in customer count. The company's 'MANTIANXING' initiative expanded to 19 fulfillment centers, generating RMB355 million in inventory value with GMV increasing 58.2% quarter-over-quarter. However, the company reported a net loss of RMB7.3 million (US$1.0 million), compared to RMB2.1 million in Q2 2024.
111, Inc. (NASDAQ: YI) has reported its Q4 and fiscal year 2024 financial results, marking significant milestones with its first-ever annual operating profit and positive operating cash flow. The company achieved income from operations of RMB2.1 million in 2024, a remarkable turnaround from an RMB350.1 million loss in 2023.
Q4 2024 net revenues were RMB3.8 billion (US$527.1 million), showing a 6.3% decrease YoY due to macroeconomic challenges. However, operating efficiency improved significantly, with total operating expenses decreasing by 470 basis points to 5.5% of net revenues.
For fiscal year 2024, net revenues reached RMB14.4 billion (US$2.0 billion), with operating expenses decreasing 230 basis points to 5.7%. The company generated positive operating cash flow of RMB263.0 million, ending the year with cash and equivalents of RMB518.3 million.
111, Inc. (NASDAQ: YI) has announced its participation in an upcoming fireside chat with Water Tower Research on March 26, 2025 at 11:00 a.m. ET. The event will feature Co-Founder, Chairman, and CEO Junling Liu discussing several key topics:
- Q4 2024 earnings results (to be reported on March 20, 2024)
- Company priorities and goals for 2025
- Updated overview of the macroenvironment
The tech-enabled healthcare platform company, focused on digitally transforming China's healthcare value chain, will host this listen-only event with WTR's senior research analyst Robert Sassoon. A replay will be available in the events section of 111's investor relations website at http://ir.111.com.cn/.
111, Inc. (NASDAQ: YI), a tech-enabled healthcare platform company in China, has scheduled the release of its unaudited financial results for Q4 and fiscal year 2024 (ended December 31, 2024) before U.S. market opens on March 20, 2025.
The company will host an earnings conference call at 7:30 AM U.S. Eastern Time (7:30 PM Beijing Time) on the same day. Participants must register in advance through the provided link to receive dial-in details. A live and archived webcast will be available, and a telephone replay will be accessible until March 27, 2025.
111, Inc. (NASDAQ: YI) has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq on February 10, 2025, that its American Depositary Shares maintained a closing bid price of $1.00 or higher for ten consecutive business days from January 24 to February 7, 2025, meeting Listing Rule 5450(a)(1) requirements. Nasdaq has officially closed this matter.
The company, which operates as a tech-enabled healthcare platform in China focusing on digitally empowering the healthcare industry's value chain, had previously faced listing compliance issues. This announcement confirms their successful resolution of the minimum bid price requirement.
111, Inc. (NASDAQ: YI) has announced plans to modify its American Depositary Shares (ADSs) ratio. The company will change the ratio from 1 ADS representing 2 Class A ordinary shares to 1 ADS representing 20 Class A ordinary shares. This change will effectively function as a one-for-ten reverse ADS split.
The underlying Class A ordinary shares will remain unchanged, with no new shares being issued or cancelled. ADS holders are not required to take any action as the change will be implemented through the ADS depositary. Trading will continue under the ticker symbol 'YI' on Nasdaq, with the ratio change expected to take effect on January 24, 2025. While the ADS price is anticipated to increase proportionally, the company cannot guarantee the post-change price will be equal to or exceed ten times the pre-change price.
111, Inc. (NASDAQ: YI) reported Q3 2024 financial results showing maintained operational profitability for the third consecutive quarter. Net revenues were RMB3.6 billion (US$513.1 million), relatively flat year-over-year. The company achieved income from operations of RMB2.4 million, compared to a loss of RMB80.4 million in the same quarter last year. Operating expenses decreased by 23.2% to RMB208.2 million, representing 5.8% of net revenues, an improvement of 160 basis points. The company maintained positive operating cash flow for three consecutive quarters, with Q3 generating RMB109.9 million.
111, Inc. (NASDAQ: YI) has announced its participation in a fireside chat with Water Tower Research on December 6, 2024 at 11:00 a.m. ET. The company's Co-Founder, Chairman, and CEO, Junling Liu, will discuss Q3 2024 earnings (to be reported on November 27, 2024), along with challenges, opportunities, and NASDAQ share price compliance issues. The tech-enabled healthcare platform company, focused on digitally transforming China's healthcare value chain, will host this listen-only event with WTR's senior research analyst Robert Sassoon. A replay will be available on 111's investor relations website.
FAQ
What is the current stock price of 111 (YI)?
What is the market cap of 111 (YI)?
